Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. reports developments tied to its commercial oncology business and selinexor-based drug development. The company markets XPOVIO (selinexor) and reports U.S. product revenue, license and other revenue, liquidity, and operating updates alongside its periodic financial results.
Recurring KPTI news also covers late-stage clinical programs evaluating selinexor in cancer indications, including the Phase 3 SENTRY trial in myelofibrosis and the Phase 3 XPORT-EC-042 trial in endometrial cancer. Company updates include clinical data presentations, regulatory-development disclosures, equity inducement grants under Nasdaq rules, financing activity, and other corporate and capital-structure matters.
Karyopharm Therapeutics (KPTI) announced significant results from the Phase 3 BOSTON study, which evaluated the once-weekly regimen of XPOVIO (selinexor), Velcade (bortezomib), and dexamethasone (SVd) in multiple myeloma patients. The study revealed a 47% increase in median progression-free survival (PFS) compared to the standard treatment. Additionally, SVd demonstrated superior overall response rates and lower rates of peripheral neuropathy. A supplemental New Drug Application has been submitted to the FDA for XPOVIO's approval as a new treatment option.
Karyopharm Therapeutics (Nasdaq: KPTI) has announced that CEO Michael Kauffman will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 9:30 a.m. ET. A live webcast of the chat will be available on the company's investor website, with a replay accessible for 90 days. Karyopharm is focused on developing innovative pharmaceuticals targeting nuclear export for cancer treatment. Their lead drug, XPOVIO®, received FDA approval in July 2019 and is part of ongoing clinical trials.
Karyopharm Therapeutics (KPTI) announced a conference call on May 29, 2020, to discuss results from the pivotal Phase 3 BOSTON study, which evaluated XPOVIO (selinexor) combined with Velcade and low-dose dexamethasone in multiple myeloma patients. The study met its primary endpoint, showing a significant increase in progression-free survival compared to the standard treatment. The results will be presented at the ASCO 2020 Virtual Scientific Program. Karyopharm has submitted a supplemental New Drug Application for XPOVIO based on these promising findings.
Karyopharm Therapeutics (Nasdaq: KPTI) announced that CEO Michael Kauffman will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020, at 8:35 a.m. ET. A live webcast will be available on their website, with a replay accessible for 90 days post-event. Karyopharm focuses on developing novel drugs targeting nuclear export for cancer treatment. Their lead drug, XPOVIO (selinexor), received FDA accelerated approval in July 2019 for multiple myeloma and is under review in Europe and for additional indications.
Karyopharm Therapeutics reported a strong first quarter of 2020, with net product sales of $16.1 million and total revenues of $18.1 million. The pivotal Phase 3 BOSTON Study achieved its primary endpoint, showing a 47% increase in progression-free survival for patients on XPOVIO compared to standard therapy. Karyopharm plans to submit a supplemental New Drug Application to the FDA by the end of May for expanded use of XPOVIO in multiple myeloma. Additionally, the FDA accepted an sNDA for selinexor in DLBCL, granting priority review, with a PDUFA action date set for June 23, 2020.
Summary not available.
Summary not available.
Summary not available.